raf inhibitor resistance mediated dimerization aberrantly spliced brafv600e 
activated ras promotes dimerization members raf kinase family- atp-competitive raf inhibitors activate erk signalling- transactivating raf dimers melanomas mutant brafv600e levels ras activation low drugs bind brafv600e monomers inhibit activity tumour-specific inhibition erk signalling results broad therapeutic index raf inhibitors remarkable clinical activity patients melanomas harbour mutant brafv600e however resistance invariably develops identify new resistance mechanism find subset cells resistant vemurafenib plx4032 rg7204 express kda variant form brafv600e p61brafv600e lacks exons region encompasses ras-binding domain p61brafv600e shows enhanced dimerization cells low levels ras activation compared full-length brafv600e cells p61brafv600e expressed endogenously ectopically erk signalling resistant raf inhibitor moreover mutation abolishes dimerization p61brafv600e restores sensitivity vemurafenib finally identified brafv600e splicing variants lacking ras-binding domain tumours six nineteen patients acquired resistance vemurafenib data support model inhibition erk signalling raf inhibitors dependent levels ras-gtp low support raf dimerization identify novel mechanism acquired resistance patients: expression splicing isoforms brafv600e dimerize ras-independent manner 
